

M.Ch. – GYNAECOLOGICAL ONCOLOGY

Paper III – PREVENTIVE ONCOLOGY AND EPIDEMIOLOGY

Q.P. Code: 181963

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. A 33 year old Infertile woman was diagnosed to have Complex atypical hyperplasia in a routine office endometrial biopsy as a part of infertility evaluation. Explain in detail the risk, prognosis and management.
2. Elaborate the Types, Indications, contraindications, Techniques, Advantages and disadvantages of various Ablative and Excisional procedures for CIN.

II. Write notes on:

(10 x 7 = 70)

1. Mucinous tumors of the ovary.
2. Tamoxifen and Endometrial cancer.
3. IOTA scoring system.
4. Cytogenetics and Pathology of Molar pregnancy.
5. Ca 125.
6. HPV vaccination.
7. Metastatic tumors to Ovary.
8. AGUS.
9. Primary HPV DNA testing Vs Co testing for Ca cervix screening.
10. Adenocarcinoma of cervix.

M.Ch. – GYNAECOLOGICAL ONCOLOGY

Paper III – PREVENTIVE ONCOLOGY AND EPIDEMIOLOGY

Q.P. Code: 181963

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: (2 x 15 = 30)

1. Discuss the strategies to eliminate cervical cancer.
2. Discuss risk reduction for ovarian cancer.

II. Write notes on: (10 x 7 = 70)

1. Age adjusted incidence.
2. Case control studies.
3. Association and Causality.
4. Risk factors for endometrial cancer.
5. Transformation zone.
6. Abnormal colposcopic findings.
7. HPV testing.
8. Management of abnormal glandular cells on cervical smear.
9. Thermocoagulation.
10. Classification and management of VIN.

(MCH 0821)

AUGUST 2021

Sub. Code: 1963

M.Ch. – GYNAECOLOGICAL ONCOLOGY

Paper III – PREVENTIVE ONCOLOGY AND EPIDEMIOLOGY

Q.P. Code: 181963

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Explain the basics of colposcopy, indications and reporting system.
2. Outline ISVVD classification. Describe vulvar intra epithelial neoplasia and its management.

II. Write notes on:

(10 x 7 = 70)

1. UKCTOCS trial.
2. Hereditary breast ovarian cancer syndrome.
3. HPV vaccines.
4. Obesity in gynaecological cancer.
5. Risk factors and pathology of breast cancer.
6. Liquid based cytology.
7. Trends in cervical cancer incidence in India.
8. Preventive methods for epithelial ovarian cancer.
9. Thromboprophylaxis in gynaec oncology.
10. Risk factors for endometrial cancer and preventive strategies.

THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY

(MCH 0822)

AUGUST 2022

Sub. Code: 1963

M.Ch. – GYNAECOLOGICAL ONCOLOGY

Paper III – PREVENTIVE ONCOLOGY AND EPIDEMIOLOGY

Q.P. Code: 181963

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: (2 x 15 = 30)

1. What are the risk factors for development of ovarian cancer? What is current evidence for screening in ovarian cancer?
2. What are the Human Papilloma virus prophylactic vaccines? Discuss the FUTURE and PATRICIA Trials.

II. Write notes on: (10 x 7 = 70)

1. What are the WHO 2020 Goals for cervical cancer prevention? Elaborate on screen and treat method.
2. IOTA ADNEX Model.
3. Risk reducing salpingoophorectomy.
4. Describe in detail the IFCPC colposcopy findings and Swedes Score.
5. Role of Artificial Intelligence in cervical cancer screening.
6. Tamoxifen – it's relevance with respect to gynaecological cancers.
7. Discuss the role of MRI in endometrial cancers.
8. Endometrial intraepithelial neoplasia.
9. Pruritis Vulva.
10. Self collected HPV.

THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY

(MCH 0124)

JANUARY 2024

Sub. Code: 1963

M.Ch. – GYNAECOLOGICAL ONCOLOGY

PAPER III – PREVENTIVE ONCOLOGY AND EPIDEMIOLOGY

Q.P. Code: 181963

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: **(2 x 15 = 30)**

1. What are the risk factors for development of cervical cancer? Discuss the epidemiology and the various strategies to eliminate cervical cancer.
2. Discuss obesity and gynaecological cancers. Discuss prevention of endometrial cancer.

II. Write notes on: **(10 x 7 = 70)**

1. Breast cancer screening.
2. Risk of malignancy index for ovarian cyst.
3. Impact of oral contraceptive pills on prevention of Gynaecological cancers.
4. Role of colony stimulating factors in prevention of bone marrow suppression.
5. Discuss the role of tumor markers in ovarian cancer.
6. Swedes score.
7. PLCO trial.
8. Tamoxifen in breast cancer.
9. Discuss the role of human papilloma virus in cervical cancer.
10. Self collection of HPV.

THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY

(MCH 0225)

FEBRUARY 2025

Sub. Code: 1963

M.Ch. BRACH XII – GYNAECOLOGICAL ONCOLOGY

PAPER III – PREVENTIVE ONCOLOGY AND EPIDEMIOLOGY

Q.P. Code: 181963

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Resource stratified screening for cervical cancer. Differentiate between see & treat and screen & treat.
2. What are the various HPV vaccines available. Discuss the evidence on the efficacy of these vaccines.

II. Write notes on:

(10 x 7 = 70)

1. Point of care HPV test.
2. Discuss the screening and prevention of cervical cancer programme in Tamil Nadu.
3. Thermal ablation.
4. Lichen sclerosis of vulva.
5. Discuss the risk reducing strategies in ovarian cancer.
6. IFCPC nomenclature of colposcopic findings. What is the SWEDE score?
7. Obesity and carcinogenesis.
8. Deep vein thrombosis prophylaxis in Gynaecological cancer.
9. Tamoxifen and its use in cancer prevention.
10. Randomized clinical trial.
